Posts tagged ALK Testing Guidelines
Adherence to National Comprehensive Cancer Network ALK Testing Guidelines for Patients with Advanced Non-Small Cell Lung Cancer in U.S. Community Medical Centers

Background: National Comprehensive Cancer Network (NCCN) guidelines recommend biomarker testing as the first step in the management of patients with advanced non-small cell lung cancer (aNSCLC). We assessed anaplastic lymphoma kinase (ALK) testing rates and factors related to underuse in community medical systems between 2012 and 2019 to understand guideline adoption. Conclusion: This analysis of real-world data shows increasing test use by year; however, one fifth of patients eligible for ALK testing still remain untested and potentially missing therapeutic options. READ ARTICLE

The Oncologist DOI:doi.org/10.1002/onco.13779

Authors: Eric H. Bernicker,Yan Xiao,Anup Abraham,Baiyu Yang,Denise A. Croix,Stella Redpath,Julia Engstrom-Melnyk,Roma Shah,Jaya Madala,Timothy C. Allen

Read More